<DOC>
	<DOC>NCT01258205</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of AMG 139 following multiple intravenous (IV) or subcutaneous (SC) dose administration in healthy subjects and in subjects with mild to severe Crohn's disease (CD).</brief_summary>
	<brief_title>Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Part A Healthy Subjects: Healthy male or female of nonreproductive potential subjects between 18 to 45 yearsofage Body mass index (BMI) between 18 and 32 kg/m2 Normal or clinically acceptable physical examination, clinical laboratory values, and ECG Additional inclusion criteria apply Part B Crohn's Subjects: Male or female subjects with CD between 18 to 55 yearsofage Body mass index (BMI) between 18 and 32 kg/m2 Normal or clinically acceptable physical examination (PE), clinical laboratory values, and ECG; clinically acceptable PE includes evidence of mild to severe CD Diagnosis of ileal or ileocolonic CD for a minimum of 6 months Mild to severe CD defined by a Crohn's Disease Activity Index (CDAI) score equal to or greater than 180 and equal to or less than 450 Elevated fecal calprotectin and CRP Additional inclusion criteria apply Parts A Healthy Subjects: History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; Recent or ongoing infection(s) Underlying condition(s) that predisposes the subject to infections History of malignancy of any type Additional exclusion criteria apply Part B only Crohn's Subjects: History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion; Recent or ongoing infection(s) Underlying condition(s) that predisposes the subject to infections History of malignancy of any type Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Amgen</keyword>
	<keyword>AMG 139</keyword>
	<keyword>Crohn's Disease</keyword>
</DOC>